Search

Your search keyword '"Ericzon, B G"' showing total 444 results
Start Over Author "Ericzon, B G"
444 results on '"Ericzon, B G"'

4. Novel benchmark values for redo liver transplantation – does the outcome justify the effort?

Author

UCL - SSS/IREC/CHEX - Pôle de chirgurgie expérimentale et transplantation, UCL - (SLuc) Service de chirurgie et transplantation abdominale, UCL - SSS/IREC - Institut de recherche expérimentale et clinique, Abbassi, F, Gero, D, Muller, X, Bueno, A, Figiel, W, Robin, F, Laroche, S, Picard, B, Shankar, S, Ivanics, T, van Reeven, M, van Leeuwen, O B, Braun, H J, Monbaliu, D, Breton, A, Vachharajani, N, Bonaccorsi Riani, Eliano, Nowak, G, McMillan, R R, Abu-Gazala, S, Nair, A, Bruballa, R, Paterno, F, Weppler Sears, D, Pinna, A D, Guarrera, J V, de Santibañes, E, de Santibañes, M, Hernandez-Aleja, R, Olthoff, K, Ghobrial, R M, Ericzon, B-G, Ciccarelli, Olga, Chapman, W C, Mabrut, J-Y, Pirenne, J, Müllhaupt, B, Ascher, N L, Porte, R J, de Meier, V E, Polak, W G, Sapisochin, G, Attia, M, Weiss, E, Adam, R A, Cherqui, D, Boudjema, K, Zienewicz, K, Jassem, W, Puhan, M, Dutkowski, P, Clavien, P-A, UCL - SSS/IREC/CHEX - Pôle de chirgurgie expérimentale et transplantation, UCL - (SLuc) Service de chirurgie et transplantation abdominale, UCL - SSS/IREC - Institut de recherche expérimentale et clinique, Abbassi, F, Gero, D, Muller, X, Bueno, A, Figiel, W, Robin, F, Laroche, S, Picard, B, Shankar, S, Ivanics, T, van Reeven, M, van Leeuwen, O B, Braun, H J, Monbaliu, D, Breton, A, Vachharajani, N, Bonaccorsi Riani, Eliano, Nowak, G, McMillan, R R, Abu-Gazala, S, Nair, A, Bruballa, R, Paterno, F, Weppler Sears, D, Pinna, A D, Guarrera, J V, de Santibañes, E, de Santibañes, M, Hernandez-Aleja, R, Olthoff, K, Ghobrial, R M, Ericzon, B-G, Ciccarelli, Olga, Chapman, W C, Mabrut, J-Y, Pirenne, J, Müllhaupt, B, Ascher, N L, Porte, R J, de Meier, V E, Polak, W G, Sapisochin, G, Attia, M, Weiss, E, Adam, R A, Cherqui, D, Boudjema, K, Zienewicz, K, Jassem, W, Puhan, M, Dutkowski, P, and Clavien, P-A

Published
2022

5. Novel benchmark values for redo liver transplantation – does the outcome justify the effort?

Author

Abbassi, F, primary, Gero, D, additional, Muller, X, additional, Bueno, A, additional, Figiel, W, additional, Robin, F, additional, Laroche, S, additional, Picard, B, additional, Shankar, S, additional, Ivanics, T, additional, van Reeven, M, additional, van Leeuwen, O B, additional, Braun, H J, additional, Monbaliu, D, additional, Breton, A, additional, Vachharajani, N, additional, Bonaccorsi Riani, E, additional, Nowak, G, additional, McMillan, R R, additional, Abu-Gazala, S, additional, Nair, A, additional, Bruballa, R, additional, Paterno, F, additional, Weppler Sears, D, additional, Pinna, A D, additional, Guarrera, J V, additional, de Santibañes, E, additional, de Santibañes, M, additional, Hernandez-Aleja, R, additional, Olthoff, K, additional, Ghobrial, R M, additional, Ericzon, B-G, additional, Ciccarelli, O, additional, Chapman, W C, additional, Mabrut, J-Y, additional, Pirenne, J, additional, Müllhaupt, B, additional, Ascher, N L, additional, Porte, R J, additional, de Meier, V E, additional, Polak, W G, additional, Sapisochin, G, additional, Attia, M, additional, Weiss, E, additional, Adam, R A, additional, Cherqui, D, additional, Boudjema, K, additional, Zienewicz, K, additional, Jassem, W, additional, Puhan, M, additional, Dutkowski, P, additional, and Clavien, P-A, additional

Published
2022
Full Text
View/download PDF

6. Recent outcome of liver transplantation for Budd Chiari syndrome - analysis of the european liver transplant registry (ELTR) and affiliated centres

Author

Dongelmans, E., Polak, Wojciech, Adam, R., Karam, Vincent, Pirenne, Jacques, Acarlı, Koray, Hakeem, A., Dhakshinamoorthy, Vignesh, Fedaruk, Dzmitry, Rummo, Oleg, Kılıç, Merve, Nordin, Arno, Fischer, L., Parente, Annalisa, Mirza, Dimitra, Bennet, William, Tokat, Yaman, Faitot, F., Antonelli, Barbara, Muiesan, Paola, Nadalin, Sivio, Berlakovich, Gabrielle, Patch, D., Berrevoet, Frederik, Ribnikar, Mojca, Gerster, Thomas, Savier, E., Gruttadauria, S., Ericzon, B. G., Cuervas-Mons, Valentin, Saborido, B. Perez, Croner, R., Magini, G., Rossi, R., Popescu, I., Razvan, Lazea, Schneeberger, S., Blokzijl, H., Llado, L., Gomez Bravo, Miguel Angel, Duvoux, Christophe, Mezjlik, V., Oniscu, G., Pearson, K., Dayangaç, Murat, Lucidi, Valerio, Detry, Olivier, Rotellar, F., and Murad, S. Darwish

Subjects
European Liver Transplant Registry (ELTR), Budd Chiari Syndrome, Liver Transplant
Published
2022

13. Improved Survival in Liver Transplant Recipients Receiving Prolonged-Release Tacrolimus in the European Liver Transplant Registry

Author

Adam, R., Karam, V., Delvart, V., Trunečka, P., Samuel, D., Bechstein, W. O., Němec, P., Tisone, G., Klempnauer, J., Rossi, M., Rummo, O. O., Dokmak, S., Krawczyk, M., Pratschke, J., Kollmar, O., Boudjema, K., Colledan, M., Ericzon, B. G., Mantion, G., Baccarani, U., Neuhaus, P., Paul, A., Bachellier, P., Zamboni, F., Hanvesakul, R., and Muiesan, P.

Published
2015
Full Text
View/download PDF

15. COVID-19 in liver transplant candidates: Pretransplant and post-transplant outcomes - An ELITA/ELTR multicentre cohort study

Author

Belli, L, Duvoux, C, Cortesi, P, Facchetti, R, Iacob, S, Perricone, G, Radenne, S, Conti, S, Patrono, D, Berlakovich, G, Hann, A, Pasulo, L, Castells, L, Faitot, F, Detry, O, Invernizzi, F, Magini, G, De Simone, P, Kounis, I, Morelli, M, Diaz Fontenla, F, Ericzon, B, Loinaz, C, Johnston, C, Gheorghe, L, Lesurtel, M, Romagnoli, R, Kollmann, D, Perera, M, Fagiuoli, S, Mirza, D, Coilly, A, Toso, C, Zieniewicz, K, Elkrief, L, Karam, V, Adam, R, Den Hoed, C, Merli, M, Puoti, M, De Carlis, L, Oniscu, G, Piano, S, Angeli, P, Fondevila, C, Polak, W, Belli L. S., Duvoux C., Cortesi P. A., Facchetti R., Iacob S., Perricone G., Radenne S., Conti S., Patrono D., Berlakovich G., Hann A., Pasulo L., Castells L., Faitot F., Detry O., Invernizzi F., Magini G., De Simone P., Kounis I., Morelli M. C., Diaz Fontenla F., Ericzon B. -G., Loinaz C., Johnston C., Gheorghe L., Lesurtel M., Romagnoli R., Kollmann D., Perera M. T. P. R., Fagiuoli S., Mirza D., Coilly A., Toso C., Zieniewicz K., Elkrief L., Karam V., Adam R., Den Hoed C., Merli M., Puoti M., De Carlis L., Oniscu G. C., Piano S., Angeli P., Fondevila C., Polak W. G., Belli, L, Duvoux, C, Cortesi, P, Facchetti, R, Iacob, S, Perricone, G, Radenne, S, Conti, S, Patrono, D, Berlakovich, G, Hann, A, Pasulo, L, Castells, L, Faitot, F, Detry, O, Invernizzi, F, Magini, G, De Simone, P, Kounis, I, Morelli, M, Diaz Fontenla, F, Ericzon, B, Loinaz, C, Johnston, C, Gheorghe, L, Lesurtel, M, Romagnoli, R, Kollmann, D, Perera, M, Fagiuoli, S, Mirza, D, Coilly, A, Toso, C, Zieniewicz, K, Elkrief, L, Karam, V, Adam, R, Den Hoed, C, Merli, M, Puoti, M, De Carlis, L, Oniscu, G, Piano, S, Angeli, P, Fondevila, C, Polak, W, Belli L. S., Duvoux C., Cortesi P. A., Facchetti R., Iacob S., Perricone G., Radenne S., Conti S., Patrono D., Berlakovich G., Hann A., Pasulo L., Castells L., Faitot F., Detry O., Invernizzi F., Magini G., De Simone P., Kounis I., Morelli M. C., Diaz Fontenla F., Ericzon B. -G., Loinaz C., Johnston C., Gheorghe L., Lesurtel M., Romagnoli R., Kollmann D., Perera M. T. P. R., Fagiuoli S., Mirza D., Coilly A., Toso C., Zieniewicz K., Elkrief L., Karam V., Adam R., Den Hoed C., Merli M., Puoti M., De Carlis L., Oniscu G. C., Piano S., Angeli P., Fondevila C., and Polak W. G.

Abstract

Objective: Explore the impact of COVID-19 on patients on the waiting list for liver transplantation (LT) and on their post-LT course. Design: Data from consecutive adult LT candidates with COVID-19 were collected across Europe in a dedicated registry and were analysed. Results: From 21 February to 20 November 2020, 136 adult cases with laboratory-confirmed SARS-CoV-2 infection from 33 centres in 11 European countries were collected, with 113 having COVID-19. Thirty-seven (37/113, 32.7%) patients died after a median of 18 (10-30) days, with respiratory failure being the major cause (33/37, 89.2%). The 60-day mortality risk did not significantly change between first (35.3%, 95% CI 23.9% to 50.0%) and second (26.0%, 95% CI 16.2% to 40.2%) waves. Multivariable Cox regression analysis showed Laboratory Model for End-stage Liver Disease (Lab-MELD) score of ≥15 (Model for End-stage Liver Disease (MELD) score 15-19, HR 5.46, 95% CI 1.81 to 16.50; MELD score≥20, HR 5.24, 95% CI 1.77 to 15.55) and dyspnoea on presentation (HR 3.89, 95% CI 2.02 to 7.51) being the two negative independent factors for mortality. Twenty-six patients underwent an LT after a median time of 78.5 (IQR 44-102) days, and 25 (96%) were alive after a median follow-up of 118 days (IQR 31-170). Conclusions: Increased mortality in LT candidates with COVID-19 (32.7%), reaching 45% in those with decompensated cirrhosis (DC) and Lab-MELD score of ≥15, was observed, with no significant difference between first and second waves of the pandemic. Respiratory failure was the major cause of death. The dismal prognosis of patients with DC supports the adoption of strict preventative measures and the urgent testing of vaccination efficacy in this population. Prior SARS-CoV-2 symptomatic infection did not affect early post-transplant survival (96%).

Published
2021

21. High frequency of autoantibodies in patients with primary sclerosing cholangitis that bind biliary epithelial cells and induce expression of CD44 and production of interleukin 6. (Liver and Biliary Disease)

Author

Xu, B., Broome, U., Ericzon, B-G, and Sumitran-Holgersson, S.

Subjects
Physiological aspects, Measurement, Autoimmune diseases -- Physiological aspects -- Measurement, Autoantibodies -- Measurement -- Physiological aspects, Cholangitis -- Physiological aspects -- Measurement
Abstract

Aim: Sera of patients with autoimmune liver diseases were investigated for the presence of autoantibodies binding to human biliary epithelial cells (BECs). Furthermore, their functional capacity was investigated by testing [...]

Published
2002

28. Tacrolimus and cyclosporine efficacy in high-risk kidney transplantation: on behalf of the European Multicentre Tacrolimus (FK506) Renal Study Group

Author

Hauser, I. A., Neumayer, H.-N., Mayer, A. D., Dmitrewski, J., Squifflet, J.-P., Besse, T., Grabensee, B., Klein, B., Eigler, F. W., Heemann, U., Pichlmayr, R., Behrend, M., Vanrenterghem, Y., Donck, J., van Hooff, J., Christiaans, M., Morales, J. M., Andres, A., Johnson, R. W. G., Short, C., Buchholz, B., Rehmert, N., Land, W., Schleibner, S., Forsythe, J. L. R., Talbot, D., Ericzon, B.-G., Brattström, C., Claesson, K., Mühlbacher, F., and Pohanka, E.

Published
1998
Full Text
View/download PDF

42. Ex Vivo Generation of Donor Antigen-Specific Immunomodulatory Cells

Author

Watanabe, M., primary, Kumagai-Braesch, Makiko, additional, Yao, M., additional, Thunberg, S., additional, Berglund, D., additional, Sellberg, F., additional, Jorns, C., additional, Enoksson, S. Lind, additional, Henriksson, J., additional, Lundgren, T., additional, Uhlin, M., additional, Berglund, E., additional, and Ericzon, B.-G., additional

Published
2018
Full Text
View/download PDF

43. Ex Vivo Generation of Donor Antigen-Specific Immunomodulatory Cells A Comparison Study of Anti-CD80/86 mAbs and CTLA4-lg Costimulatory Blockade

Author

Watanabe, M., Kumagai-Braesch, Makiko, Yao, M., Thunberg, S., Berglund, David, Sellberg, Felix, Jorns, C., Enoksson, S. Lind, Henriksson, J., Lundgren, T., Uhlin, M., Berglund, E., Ericzon, B-G, Watanabe, M., Kumagai-Braesch, Makiko, Yao, M., Thunberg, S., Berglund, David, Sellberg, Felix, Jorns, C., Enoksson, S. Lind, Henriksson, J., Lundgren, T., Uhlin, M., Berglund, E., and Ericzon, B-G

Abstract

Adoptive transfer of alloantigen-specific immunomodulatory cells generated ex vivo with anti-CD80/CD86 mAbs (2D10.4/IT2.2) holds promise for operational tolerance after transplantation. However, good manufacturing practice is required to allow widespread clinical application. Belatacept, a clinically approved cytotoxic T-lymphocyte antigen 4-immunoglobulin that also binds CD80/CD86, could be an alternative agent for 2D10.4/IT2.2. With the goal of generating an optimal cell treatment with clinically approved reagents, we evaluated the donor-specific immunomodulatory effects of belatacept- and 2D10.4/IT2.2-generated immunomodulatory cells. Immunomodulatory cells were generated by coculturing responder human peripheral blood mononuclear cells (PBMCs) (50 x 10(6) cells) with irradiated donor PBMCs (20 x 10(6) cells) from eight human leukocyte antigen-mismatched responder-donor pairs in the presence of either 2D10.4/IT2.2 (3 mu g/10(6) cells) or belatacept (40 mu g/10(6) cells). After 14 days of coculture, the frequencies of CD4(+) T cells, CD8(+) T cells, and natural killer cells as well as interferon gamma (IFN-gamma) production in the 2D10.4/IT2.2- and belatacept-treated groups were lower than those in the control group. The percentage of CD19(+) B cells was higher in the 2D10.4/IT2.2- and belatacept-treated groups than in the control group. The frequency of CD4(+)CD25(+)CD127(low)FOXP3(+) T cells increased from 4.1 +/- 1.0% (preculture) to 7.1 +/- 2.6% and 7.3 +/- 2.6% (day 14) in the 2D10.4/IT2.2- and belatacept-treated groups, respectively (p<0.05). Concurrently, delta-2 FOXP3 mRNA expression increased significantly. Compared with cells derived from the no-antibody treated control group, cells generated from both the 2D10.4/IT2.2- and belatacept-treated groups produced lower IFN-gamma and higher interleukin-10 levels in response to donor-antigens, as detected by enzyme-linked immunospot. Most importantly, 2D10.4/IT2.2- and belatacept-generated cells effectively

Published
2018
Full Text
View/download PDF

44. 2018 Annual Report of the European Liver Transplant Registry (ELTR) – 50-year evolution of liver transplantation

Author

Adam, R, Karam, V, Cailliez, V, O Grady, J, Mirza, D, Cherqui, D, Klempnauer, J, Salizzoni, M, Pratschke, J, Jamieson, N, Hidalgo, E, Paul, A, Andujar, R, Lerut, J, Fisher, L, Boudjema, K, Fondevila, C, Soubrane, O, Bachellier, P, Pinna, A, Berlakovich, G, Bennet, W, Pinzani, M, Schemmer, P, Zieniewicz, K, Romero, C, De Simone, P, Ericzon, B, Schneeberger, S, Wigmore, S, Prous, J, Colledan, M, Porte, R, Yilmaz, S, Azoulay, D, Pirenne, J, Line, P, Trunecka, P, Navarro, F, Lopez, A, De Carlis, L, Pena, S, Kochs, E, Duvoux, C, Adam R., Karam V., Cailliez V., O Grady J. G., Mirza D., Cherqui D., Klempnauer J., Salizzoni M., Pratschke J., Jamieson N., Hidalgo E., Paul A., Andujar R. L., Lerut J., Fisher L., Boudjema K., Fondevila C., Soubrane O., Bachellier P., Pinna A. D., Berlakovich G., Bennet W., Pinzani M., Schemmer P., Zieniewicz K., Romero C. J., De Simone P., Ericzon B. -G., Schneeberger S., Wigmore S. J., Prous J. F., Colledan M., Porte R. J., Yilmaz S., Azoulay D., Pirenne J., Line P. -D., Trunecka P., Navarro F., Lopez A. V., De Carlis L., Pena S. R., Kochs E., Duvoux C., Adam, R, Karam, V, Cailliez, V, O Grady, J, Mirza, D, Cherqui, D, Klempnauer, J, Salizzoni, M, Pratschke, J, Jamieson, N, Hidalgo, E, Paul, A, Andujar, R, Lerut, J, Fisher, L, Boudjema, K, Fondevila, C, Soubrane, O, Bachellier, P, Pinna, A, Berlakovich, G, Bennet, W, Pinzani, M, Schemmer, P, Zieniewicz, K, Romero, C, De Simone, P, Ericzon, B, Schneeberger, S, Wigmore, S, Prous, J, Colledan, M, Porte, R, Yilmaz, S, Azoulay, D, Pirenne, J, Line, P, Trunecka, P, Navarro, F, Lopez, A, De Carlis, L, Pena, S, Kochs, E, Duvoux, C, Adam R., Karam V., Cailliez V., O Grady J. G., Mirza D., Cherqui D., Klempnauer J., Salizzoni M., Pratschke J., Jamieson N., Hidalgo E., Paul A., Andujar R. L., Lerut J., Fisher L., Boudjema K., Fondevila C., Soubrane O., Bachellier P., Pinna A. D., Berlakovich G., Bennet W., Pinzani M., Schemmer P., Zieniewicz K., Romero C. J., De Simone P., Ericzon B. -G., Schneeberger S., Wigmore S. J., Prous J. F., Colledan M., Porte R. J., Yilmaz S., Azoulay D., Pirenne J., Line P. -D., Trunecka P., Navarro F., Lopez A. V., De Carlis L., Pena S. R., Kochs E., and Duvoux C.

Abstract

The purpose of this registry study was to provide an overview of trends and results of liver transplantation (LT) in Europe from 1968 to 2016. These data on LT were collected prospectively from 169 centers from 32 countries, in the European Liver Transplant Registry (ELTR) beginning in 1968. This overview provides epidemiological data, as well as information on evolution of techniques, and outcomes in LT in Europe over more than five decades; something that cannot be obtained from only a single center experience.

Published
2018

45. Decreasing incidence of cancer after liver transplantation:A Nordic population-based study over 3 decades

Author

Nordin, A., Åberg, F., Pukkala, E., Pedersen, C. R., Storm, H. H., Rasmussen, A., Bennet, W., Olausson, M., Wilczek, H., Ericzon, B. G., Tretli, S., Line, P. D., Karlsen, T. H., Boberg, K. M., Isoniemi, H., Nordin, A., Åberg, F., Pukkala, E., Pedersen, C. R., Storm, H. H., Rasmussen, A., Bennet, W., Olausson, M., Wilczek, H., Ericzon, B. G., Tretli, S., Line, P. D., Karlsen, T. H., Boberg, K. M., and Isoniemi, H.

Abstract

Cancer remains one of the most serious long-term complications after liver transplantation (LT). Data for all adult LT patients between 1982 and 2013 were extracted from the Nordic Liver Transplant Registry. Through linkage with respective national cancer-registry data, we calculated standardized incidence ratios (SIRs) based on country, sex, calendar time, and age-specific incidence rates. Altogether 461 cancers were observed in 424 individuals of the 4246 LT patients during a mean 6.6-year follow-up. The overall SIR was 2.22 (95% confidence interval [CI], 2.02-2.43). SIRs were especially increased for colorectal cancer in recipients with primary sclerosing cholangitis (4.04) and for lung cancer in recipients with alcoholic liver disease (4.96). A decrease in the SIR for cancers occurring within 10 years post-LT was observed from the 1980s: 4.53 (95%CI, 2.47-7.60), the 1990s: 3.17 (95%CI, 2.70-3.71), to the 2000s: 1.76 (95%CI, 1.51-2.05). This was observed across age- and indication-groups. The sequential decrease for the SIR of non-Hodgkin lymphoma was 25.0-12.9-7.53, and for nonmelanoma skin cancer 80.0-29.7-10.4. Cancer risk after LT was found to be decreasing over time, especially for those cancers that are strongly associated with immunosuppression. Whether immunosuppression minimization contributed to this decrease merits further study.

Published
2018

49. Characterization of infiltrating lymphocytes in human benign and malignant prostate tissue

Author

Rådestad, E., Egevad, L., Jorns, C., Mattsson, J., Sundberg, B., Nava, S., Ericzon, B. -G, Henningsohn, L., Levitsky, V., Uhlin, Michael, Rådestad, E., Egevad, L., Jorns, C., Mattsson, J., Sundberg, B., Nava, S., Ericzon, B. -G, Henningsohn, L., Levitsky, V., and Uhlin, Michael

Abstract

Immune checkpoint blockade has shown promising results in numerous cancer types. However, in prostate cancer (PC), absent or limited responses have been reported. To investigate further, we compared the phenotype of infiltrating T-cells isolated from prostate tissue from patients with PC (n = 5), benign prostatic hyperplasia (BPH) (n = 27), BPH with concurrent PC (n = 4) and controls (n = 7). The majority of T-cells were CD8+ and had a CCR7-CD45RO+ effector memory phenotype. However, the yield of T-cells isolated from PC lesions was on average 20-fold higher than that obtained from control prostates. Furthermore, there were differences between the prostate conditions regarding the percentage of T-cells expressing several activation markers and co-inhibitory receptors. In conclusion, many prostateinfiltrating T-cells express co-inhibitory receptors PD-1 and LAG-3, regardless of prostate condition. Despite the observed increase in counts and percentages of PD- 1+ T-cells in PC, the concomitant demonstration of high percentage of PD-1+ T-cells in control prostates suggests that PD-1 may play a role in controlling the homeostasis of the prostate rather than in contributing to PC-associated immune-suppression. Thus, PD-1 may not be a good candidate for checkpoint blockade in PC and these data are relevant for evaluation of clinical trials and in designing future immunotherapeutic approaches of PC., QC 20171024

Published
2017
Full Text
View/download PDF

50. Technical Aspects of Liver Transplantation - A Survey-Based Study within the Eurotransplant, Swisstransplant, Scandiatransplant and British Transplantation Society Networks

Author

Czigany, Z., Schoening, W., Ulmer, T. F., Bednarsch, J., Schnitzbauer, A., Scherer, M. N., Guba, M., Klempnauer, J., Nadalin, S., Herden, U., Lang, H., Paul, A., Pratschke, J., Seehofer, D., Glanemann, M., Braun, F., Senninger, N., Settmacher, U., Bruns, C., Mehrabi, A., Pirenne, J., Berlakovich, G. A., Schneeberger, S., Rogiers, X., Lucidi, V., Meurisse, M., Skegro, M., Mathe, Z., Veselko, M., Tomazic, A., Dutkowski, P., Banz-Wuethrich, V., Line, P. -D., Ericzon, B. -G., Malago, M., Heaton, N., Neumann, U. P., Lurje, G., Czigany, Z., Schoening, W., Ulmer, T. F., Bednarsch, J., Schnitzbauer, A., Scherer, M. N., Guba, M., Klempnauer, J., Nadalin, S., Herden, U., Lang, H., Paul, A., Pratschke, J., Seehofer, D., Glanemann, M., Braun, F., Senninger, N., Settmacher, U., Bruns, C., Mehrabi, A., Pirenne, J., Berlakovich, G. A., Schneeberger, S., Rogiers, X., Lucidi, V., Meurisse, M., Skegro, M., Mathe, Z., Veselko, M., Tomazic, A., Dutkowski, P., Banz-Wuethrich, V., Line, P. -D., Ericzon, B. -G., Malago, M., Heaton, N., Neumann, U. P., and Lurje, G.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results